The metabolic syndrome, omega-3 fatty acids and inflammatory processes in relation to schizophrenia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 4-5, 2006, Pages 323-327

  Peet, Malcolm ^a  

^a ROTHERHAM DONCASTER AND SOUTH HUMBER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

ARTICLE; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FATTY ACID SYNTHESIS; HEREDITY; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NUTRITION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA;

ARTHRITIS, RHEUMATOID; CORONARY DISEASE; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS; METABOLIC SYNDROME X; SCHIZOPHRENIA;

EID: 33748983004     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.07.013     Document Type: Article

References (53)

1. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br. J. Psychiatry 184 Suppl. 47 (2004) s64-s66
2. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl. 1 (2005) 1-93
3. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
4. Gough S., and Peveler R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br. J. Psychiatry 184 Suppl. 47 (2004) s106-s111
5. Goff D.C., Sullivan L.M., EcEvoy J.P., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. (2005)
6. Brown S., Inskip H., and Barraclough B. Causes of the excess morality of schizophrenia. Br. J. Psychiatry 177 (2000) 212-217
7. Joukamaa M., Heliovaara M., Knett P., Aromaa A., Raitasalo R., and Lehtinen V. Mental disorders and cause-specific mortality. Br. J. Psychiatry 179 (2001) 498-502
8. World Health Organisation. Diet, Nutrition and the Prevention of Chronic Diseases (2003), WHO, Geneva
9. O'Dea K. Westernisation, insulin resistance and diabetes in Australian aborigines. Med. J. Aust. 155 (1991) 258-264
10. Mann J.I. Diet and risk of coronary heart disease and type 2 diabetes. Lancet 60 (2002) 783-789
11. McCreadie R., MacDonald E., Blakelock C., et al. Dietary intake of schizophrenia patients in Nithsdale, Scotland: a case-control study. Br. Med. J. 317 (1998) 784-785
12. Brown S., Birtwistle L.R., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 (1999) 697-701
13. Daumit G.L., Goldberg R.W., Anthony C., et al. Physical activity patterns in adults with severe mental illness. J. Nerv. Ment. Dis. 193 (2005) 641-646
14. Gothelf D., Falk B., Singer P., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent inpatients treated with olanzapine. Am. J. Psychiatry 159 (2002) 1055-1057
15. Kelly C., and McCreadie R.G. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am. J. Psychiatry 156 (1999) 1751-1757
16. Hopper K., and Wanderlung J. Revisiting the developed versus developing country distinction in course and outcome of schizophrenia: results from ISOS, the WHO collaborative follow-up project. Schizophr. Bull. 26 (2000) 835-846
17. Tucker K.L., and Burapanin S. Nutrition and ageing in developing countries. J. Nutr. 131 (2001) 2417S-2423S
18. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to dietary practices: an ecological study. Br. J. Psychiatry 184 (2004) 404-408
19. Christensen O., and Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 78 (1988) 587-591
20. Mukherjee S., Schnur D.B., and Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet i (1989) 495
21. Gough S.C.L., and Donovan M.C.O. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J. Psychopharmacol. 19 Suppl. (2005) 47-55
22. Pan D.A., Lillioja S., Milner M.R., et al. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J. Clin. Invest. 96 (1995) 2802-2808
23. Andersson A., Nälsén C., Tengblad S., and Vessby B. Fatty acid composition of skeletal muscle reflects dietary fat composition in humans. Am. J. Clin. Nutr. 76 (2002) 1222-1229
24. Min Y., Ghebremeskel K., Lowy C., Thomas B., and Crawford M.A. Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes. Diabetologia 47 (2004) 75-81
25. Paganelli F., Maixent J.M., Duran M.J., Parhizgar R., Pieroni G., and Sennoune S. Altered erythrocyte n-3 fatty acid levels in Mediterranean patients with coronary artery disease. Int. J. Cardiol. 78 (2001) 27-32
26. Peet M., Shah S., Selvam K., and Ramchand C.N. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J. Biol. Psychiatry 5 (2004) 92-99
27. Hu F.B., Bronner L., Willett W.C., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. J. Am. Med. Assoc. 287 (2002) 1815-1821
28. Erkkilä A.T., Lichtenstein A.H., Mozaffarian D., and Herrington D.H. Fish intake is associated with reduced progression of coronary artery atterosclerosis in postmenopausal women with coronary artery disease. Am. J. Clin. Nutr. 80 (2004) 626-632
29. Nettleson J.A., and Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J. Am. Diet. Assoc. 105 (2005) 428-440
30. Peet M., and Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 65 (2005) 1051-1059
31. Vidgren H.M., Agren J.J., Schwab U., Rissanen T., Hanninen O., and Uusitupa M.I. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil and docosahexaenoic acid-rich oil among healthy young men. Lipids 32 (1997) 697-705
32. Cho H.P., Nakamura M.T., and Clarke S.D. Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. J. Biol. Chem. 274 (1999) 471-477
33. Lomnitski L., Oron L., Skelton D., and Michaelson D.M. Distinct alterations in phospholipid metabolism in brains of apolipoprotein E-deficient mice. J. Neurosci. Res. 58 (1999) 586-572
34. Sampath H., and Ntambi J.M. Polyunsaturated fatty acid regulation of gene expression. Nutr. Rev. 62 (2004) 333-339
35. Hibbeln J.R., Makino K.K., Martin C.E., Dickerson F., Boronow J., and Fenton W.S. Smoking, gender and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorders. Biol. Psychiatry 53 (2003) 431-441
36. Pawlowsky R.J., Bacher J., and Salem N. Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low n-3 fatty acid diet. Alcohol Clin. Exp. Res. 25 (2001) 1758-1765
37. Torrey E.F., and Yolken R.H. The schizophrenia- rheumatoid arthritis connection: infectious, immune, or both?. Brain Behav. Immun. 15 (2001) 401-410
38. Peet M. Nutrition and schizophrenia: epidemiological and clinical perspectives. Nutr. Health 17 (2003) 211-219
39. Hanson D.R., and Gothesman H. Theories of schizophrenia: a genetic-inflammatory-hypothesis. BMC Med. Genet. 6 (2005) 7
40. Riedel M., Strassing M., Schurarz M.J., and Muller N. Cox-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 10 (2005) 805-819
41. Oken R.J., and Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr. Bull. 25 (1999) 625-638
42. Kronig H., Riedel M., Schwarz M.J., et al. ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. Neuroimmunomdulation 12 (2005) 54-59
43. Klimiuk P.A., Sierakowski S., Latosiewicz R., et al. Soluble adhesion molecules (ICAM-1, VCAM-1 and E-selection) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann. Rheum. Dis. 61 (2002) 804-809
44. Horrobin D.F. Schizophrenia: the illness that made us human. Med. Hypotheses 50 (1998) 269-288
45. Crow T.J. Is schizophrenia the price that homo sapiens pays for language?. Schizophr. Res. 28 (1997) 127-141
46. Chou H.-H., Hayakawa T., Diaz S., et al. Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc. Natl. Acad. Sci. USA 99 (2002) 11736-11741
47. Varki A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences and implications for hominid evolution. Am. J. Phys. Anthropol. 33 Suppl. (2001) 54-69
48. Kirov G., O'Donovan M.C., and Owen M.J. Finding schizophrenia genes. J. Clin. Invest. 115 (2005) 1440-1448
49. Jawaheer D., Seldin M.F., Imos C.I., et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum. 48 (2003) 906-916
50. Stone W.S., Faraone S.V., Su J., Tarbox S.I., Van Eeerdewegh P., and Tsuang M.T. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127 (2004) 5-10
51. Molteni R., Barnard R.J., Ying Z., Roberts C.K., and Gomez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112 (2002) 803-814
52. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogernsis and therapy of schizophrenia. Eur. Neuropsychoparmacol. 15 (2005) 319-329
53. Mattson M.P. Energy intake, meal frequency, and health: a neurobological perspective. Annu. Rev. Nutr. 25 (2005) 237-260